Background:
Several studies have explored the prognostic value of MicroRNA-153 (miR-153) in various cancers, but obtained inconsistent results. Thus, we conducted a meta-analysis to assess the prognostic significance of miR-153 for patients with cancer.
Methods:
Eligible studies were identified by searching the online databases Pubmed, Embase, Web of Science, Medline,and the China National Knowledge Infrastructure (CNKI) up to March 2020. Hazard ratios (HRs) with 95% CIs and were calculated to clarify the correlation between miR-153 expression and prognosis of different cancers. Odds ratios (ORs) with 95% CI were selected to appraise the correlation between miR-153 with clinicopathological characteristics of cancer patients.
Results:
In total, 933 patients from 11 articles were enrolled in our meta-analysis. The results revealed that low miR-153 expression was significantly correlated with poor overall survival (OS) (HR = 2.45, 95% CI = 1.66–3.63,
P
< .001), but not with disease-free survival (DFS) (HR = 1.67, 95% CI = 0.45–6.19,
P
= .442). Subgroup analysis found that low miR-153 expression was associated with worse OS in the reported directly from articles group (HR = 2.67, 95% CI: 1.32–5.37,
P
= .006), survival curves group (HR = 2.10, 95% CI: 1.56–2.84,
P
< .001), digestive system tumor (HR = 2.76, 95% CI: 1.73–4.41,
P
< .001), and breast cancer (HR = 4.01, 95% CI: 1.46–11.04,
P
= .007).
Moreover, cancer patients with low miR-153 expression were prone to poor tumor differentiation(poor vs well+moderate, OR = 2.41, 95% CI = 1.52–3.82,
P
< .001), earlier lymph node metastasis (present vs absent, OR = 2.19, 95% CI = 1.12–4.25,
P
= .021) and earlier distant metastasis (present vs absent,OR = 8.24, 95% CI = 2.93–23.21,
P
< .001), but not associated with age,gender and TNM stage.
Conclusions:
This meta-analysis indicated that low miR-153 expression is associated with poor prognosis. miR-153 may serve as an effective predictive biomarker for tumor prognosis, especially for digestive system tumor and breast cancer.